Biotechnology and Pharmaceuticals

October 05, 2018

Companies covered: Gilead Sciences, Inc. (NASDAQ:GILD), Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), Cymabay Therapeutics Inc. (NASDAQ:CBAY), Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), ChemoCentryx, Inc. (NASDAQ:CCXI), Five Prime Therapeutics, Inc. (NASDAQ:FPRX), Allergan, Inc. (NYSE:AGN), AbbVie Inc. (NYSE:ABBV), Genfit SA (OTCMKTS:GNFTF), Viking Therapeutics (NASDAQ:VKTX), Madrigal Pharmaceuticals (NASDAQ:MDGL), InflaRx NV (NASDAQ:IFRX), Ra Pharmaceuticals (NASDAQ:RARX), Jounce Therapeutics (NASDAQ:JNCE), Arcus Biosciences (NYSE:RCUS), ObsEva SA (NASDAQ:OBSV), Kindred Biosciences, Inc. (NASDAQ:KIN), NuCana plc (NASDAQ:NCNA), Verastem, Inc. (NASDAQ:VSTM), Cerecor Inc. (NASDAQ:CERC), Avenue Therapeutics, Inc. (NASDAQ:ATXI), CEL-SCI Corporation (NYSEAMERICAN:CVM), ImmuCell Corporation (NASDAQ:ICCC), Moleculin Biotech, Inc. (NASDAQ:MBRX), Innovest Global, Inc. (OTCMKTS:IVST), CytoDyn Inc. (OTCMKTS:CYDY), Immutep Limited (NASDAQ:IMMP), ERYTECH Pharma (NASDAQ:ERYP), Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB), Aquestive Therapeutics (NASDAQ:AQST)

Buy ($175)